Seedlabs
Source research

Gambogic amide, a selective agonist for TrkA receptor that possesses robust neurotrophic activity, prevents neuronal cell death

Sung‐Wuk Jang, Masashi Okada, Iqbal Sayeed, Ge� Xiao, Donald G. Stein, Peng Jin et al. · 2007 · 164 citationsRead the paper

Nerve growth factor (NGF) binds to TrkA receptor and triggers activation of numerous signaling cascades, which play critical roles in neuronal plasticity, survival, and neurite outgrowth. To mimic NGF functions pharmacologically, we developed a high-throughput screening assay to identify small-molecule agonists for TrkA receptor. The most potent compound, gambogic amide, selectively binds to TrkA, but not TrkB or TrkC, and robustly induces its tyrosine phosphorylation and downstream signaling activation, including Akt and MAPKs. Further, it strongly prevents glutamate-induced neuronal cell death and provokes prominent neurite outgrowth in PC12 cells. Gambogic amide specifically interacts with the cytoplasmic juxtamembrane domain of TrkA receptor and triggers its dimerization. Administration of this molecule in mice substantially diminishes kainic acid-triggered neuronal cell death and decreases infarct volume in the transient middle cerebral artery occlusion model of stroke. Thus, gambogic amide might not only establish a powerful platform for dissection of the physiological roles of NGF and TrkA receptor but also provide effective treatments for neurodegenerative diseases and stroke.

1 idea Seedlabs derived from this research

A pharmaceutical compound designed as a selective TrkB receptor agonist to induce neuroplasticity and antidepressant effects without activating 5-HT2A receptors. The approach focuses on mimicking BDNF-mediated resilience to stress while managing potential receptor interference and oncogenic risks.

AI score 81/100